Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. Jentashapir Journal of Cellular and Molecular Biology
  4. Articles

  5. Anti-cancer Properties of Myricetin Against HT-29 Colon Cancer Cells Through Regulation of RIPK1/RIPK3 Signaling Pathway
  6. Scopus by Title (Ref)

Jentashapir Journal of Cellular and Molecular Biology

Official Journal of Ahvaz Jundishapur University of Medical Sciences

homeHome
play_circleCurrent IssuelistAll Issuesformat_indent_increaseIn PresssearchSearchcheck_circleAccepted Manuscripts
settingsInstructions
groupsEditors & BoardsinfoJournal InformationemailSupportshareIndexing and Listing Sourcesassignment_indReviewer and AE Registration Formshow_chartJournal MetricsbalancePublication Ethics and Malpractice StatementphoneContact Uszoom_inOpen Peer Review (OPR)
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Current State of Knowledge of the Anticancer Properties of Polyphenolic Compounds from Garlic (Allium sativum L.)

- Binduga U. , et al.

2. The selective proapoptotic impact of the myricetin-loaded alginate-cellulose hybrid nanocrystals (MAC-NCs) on the human AGS gastric cancer cells

- Teimouri M. , et al.

HomeInstructions

Articles

  • Current Issue
  • All Issues
  • In Press
  • Search
  • Accepted Manuscripts

About Journal

  • Editors & Boards
  • Journal Information
  • Support
  • Indexing and Listing Sources
  • Reviewer and AE Registration Form
  • Journal Metrics
  • Publication Ethics and Malpractice Statement
  • Contact Us
  • Open Peer Review (OPR)
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.